What did Prime Therapeutics pay for MagellenRx?

Prime Therapeutics acquired MagellenRx for $1.35B in 2022 (11.8x EBITDA), equivalent to 0.50x revenue. Target revenue was approximately $2598.6M. Target EBITDA was approximately $114.5M.

What does MagellenRx do?

MagellenRx is a pharmacy business.

What multiple did Prime Therapeutics pay for MagellenRx?

11.8x EBITDA and 0.50x revenue, based on disclosed deal value of $1.35B and disclosed financials.

M&A TRANSACTION · 2022

MagellenRx acquired by Prime Therapeutics

$1.35B· 11.8x EBITDA· 0.50x revenue

Target

MagellenRx

Acquirer

Prime Therapeutics

Strategic buyer

Disclosed financials at time of acquisition

Revenue

$2598.6M

EBITDA

$114.5M

Deal Value

$1.35B

EV/EBITDA

11.8x

Context

This $1.35B acquisition of MagellenRx by Prime Therapeutics sits in the pharmacy sub-vertical. The 11.8x EBITDA multiple paid in 2022 can be compared against the population median for pharmacy transactions of similar size on our Pharmacy valuation hub. Prime Therapeutics is acquiring as a strategic buyer; see how strategic acquirers typically price pharmacy businesses on our Pharmacy strategic buyer-pool page.

Source

Data sourced from Press releases and SEC filings. All figures reflect disclosed values at the time of the acquisition; no estimated or imputed data. Methodology

Value your own pharmacy

Get an instant valuation range for your business. Backed by 25,592 real M&A transactions.

Compare your business to the MagellenRx acquisition.

Citation: ExitValue.ai. (2022). MagellenRx acquired by Prime Therapeutics. https://exitvalue.ai/deals/magellenrx-acquired-by-prime-therapeutics-hc-2022-0068